Patient Preference Study

Phase 3CompletedNCT00576342

Alcon Research129 enrolled

Overview

In this randomized crossover study, patients will receive a single drop of two test articles and assess comfort.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

129

Conditions

Glaucoma Ocular Hypertension

Interventions

AL-3862+timolol ophthalmic suspensionDRUG

Dorzolamide+timolol ophthalmic solutionDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Sign informed consent; * Diagnosis of glaucoma or ocular hypertension; * On a stable regimen of any intraocular pressure (IOP) lowering medication (mono-therapy); * IOP for which, in the opinion of the investigator, participation in the study does not present a risk to ocular health; * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Best corrected visual acuity worse than 0.60 logMAR (20/80 Snellen) in either eye; * Pregnant, nursing, or not using highly effective birth control methods; * Use of oral or topical corticosteroids within 30 days of the Screening Visit and during the course of the study; * History of bronchial asthma or severe chronic obstructive pulmonary disease; * Other protocol-defined exclusion criteria may apply.

Outcomes

Primary Outcomes

Percentage of patients with a stated preference for either study medication

Time frame: Day 2

Secondary Outcomes

Mean ocular discomfort score

Time frame: Day 1, 1 minute after drop instillation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.